Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead precision cancer therapy into Phase II – an asset it licensed from Bristol-Myers Squibb.
Ayala Pharma, an Israeli oncology company built around targeted cancer therapies licensed from Bristol-Myers Squibb Co., has raised $17m to take its lead asset into Phase II trials.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
